Olema Pharmaceuticals, Inc.
As of Oct 22, 2026, Olema Pharmaceuticals is in Stage 4, the downtrend phase, now in week 6 (since Sep 16, 2026). It closed at $7.02, 80.4% below its 52-week high and below its 200-day average, which is falling.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is OLMA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
OLMA among Biotechnology233rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …233 | OLMA | Stage 4 · wk 6 | 43 | −20.5% |
Olema Pharmaceuticals: quick answers
What stage is Olema Pharmaceuticals in?
As of Oct 22, 2026, Olema Pharmaceuticals (OLMA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Olema Pharmaceuticals in an uptrend?
No. Olema Pharmaceuticals is in a Stage 4 downtrend. It trades 52.1% below its 200-day average, which is falling.
How far is Olema Pharmaceuticals from its 52-week high?
Olema Pharmaceuticals closed at $7.02 on Oct 22, 2026, 80.4% below its 52-week high of $35.83. Its 52-week low is $6.58.
How has Olema Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Olema Pharmaceuticals is down 15.2% over the past year and down 72.2% so far in 2026.
Which sector and industry is Olema Pharmaceuticals in?
Olema Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.